270 related articles for article (PubMed ID: 18585397)
1. Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens.
Ohno Y; Shimizu S; Imaki J; Ishihara S; Sofue N; Sasa M; Kawai Y
Neuropharmacology; 2008 Oct; 55(5):717-23. PubMed ID: 18585397
[TBL] [Abstract][Full Text] [Related]
2. Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders.
Shimizu S; Tatara A; Imaki J; Ohno Y
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):877-81. PubMed ID: 20398719
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the antibradykinetic actions of 5-HT1A agonists using the mouse pole test.
Ohno Y; Shimizu S; Imaki J; Ishihara S; Sofue N; Sasa M; Kawai Y
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jul; 32(5):1302-7. PubMed ID: 18495311
[TBL] [Abstract][Full Text] [Related]
4. F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.
Bruins Slot LA; Lestienne F; Grevoz-Barret C; Newman-Tancredi A; Cussac D
Eur J Pharmacol; 2009 Oct; 620(1-3):27-35. PubMed ID: 19695244
[TBL] [Abstract][Full Text] [Related]
5. Somatodendritic and postsynaptic serotonin-1A receptors in the attenuation of haloperidol-induced catalepsy.
Haleem DJ; Shireen E; Haleem MA
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1323-9. PubMed ID: 15588759
[TBL] [Abstract][Full Text] [Related]
6. Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist.
Ohno Y; Okano M; Imaki J; Tatara A; Okumura T; Shimizu S
Pharmacol Biochem Behav; 2010 Aug; 96(2):175-80. PubMed ID: 20460137
[TBL] [Abstract][Full Text] [Related]
7. R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum.
Ichikawa J; Meltzer HY
J Pharmacol Exp Ther; 1999 Dec; 291(3):1227-32. PubMed ID: 10565846
[TBL] [Abstract][Full Text] [Related]
8. Role of NMDA receptor subtypes in the induction of catalepsy and increase in Fos protein expression after administration of haloperidol.
Yanahashi S; Hashimoto K; Hattori K; Yuasa S; Iyo M
Brain Res; 2004 Jun; 1011(1):84-93. PubMed ID: 15140647
[TBL] [Abstract][Full Text] [Related]
9. Effects of tandospirone, a 5-HT1A agonistic anxiolytic agent, on haloperidol-induced catalepsy and forebrain Fos expression in mice.
Ohno Y; Shimizu S; Imaki J
J Pharmacol Sci; 2009 Apr; 109(4):593-9. PubMed ID: 19352073
[TBL] [Abstract][Full Text] [Related]
10. Effect of 5-HT(1A) receptor ligands on Fos-like immunoreactivity in rat brain: evidence for activation of noradrenergic transmission.
Hajós-Korcsok E; Sharp T
Synapse; 1999 Nov; 34(2):145-53. PubMed ID: 10502313
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of serotonin-1A receptor dependent responses following withdrawal of haloperidol in rats.
Haleem DJ; Khan NH
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Jun; 27(4):645-51. PubMed ID: 12787852
[TBL] [Abstract][Full Text] [Related]
12. Involvement of 5-hydroxytryptamine1A receptors in Delta9-tetrahydrocannabinol-induced catalepsy-like immobilization in mice.
Egashira N; Matsuda T; Koushi E; Mishima K; Iwasaki K; Shoyama Y; Fujiwara M
Eur J Pharmacol; 2006 Nov; 550(1-3):117-22. PubMed ID: 17022969
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
[TBL] [Abstract][Full Text] [Related]
14. The counteraction of opioid-induced ventilatory depression by the serotonin 1A-agonist 8-OH-DPAT does not antagonize antinociception in rats in situ and in vivo.
Guenther U; Manzke T; Wrigge H; Dutschmann M; Zinserling J; Putensen C; Hoeft A
Anesth Analg; 2009 Apr; 108(4):1169-76. PubMed ID: 19299781
[TBL] [Abstract][Full Text] [Related]
15. Serotonin(1A) receptor agonism in the expression of behavioral dopaminergic supersensitivity in subchronic haloperidol treated rats.
Batool F; Haleem DJ
Pak J Pharm Sci; 2008 Oct; 21(4):411-20. PubMed ID: 18930864
[TBL] [Abstract][Full Text] [Related]
16. 5-HT1A agonist alleviates serotonergic potentiation of extrapyramidal disorders via postsynaptic mechanisms.
Shimizu S; Mizuguchi Y; Tatara A; Kizu T; Andatsu S; Sobue A; Fujiwara M; Morimoto T; Ohno Y
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():86-91. PubMed ID: 23838274
[TBL] [Abstract][Full Text] [Related]
17. The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens.
Ichikawa J; Meltzer HY
Brain Res; 2000 Mar; 858(2):252-63. PubMed ID: 10708676
[TBL] [Abstract][Full Text] [Related]
18. Bidirectional modulation of classical fear conditioning in mice by 5-HT(1A) receptor ligands with contrasting intrinsic activities.
Youn J; Misane I; Eriksson TM; Millan MJ; Ogren SO; Verhage M; Stiedl O
Neuropharmacology; 2009; 57(5-6):567-76. PubMed ID: 19607850
[TBL] [Abstract][Full Text] [Related]
19. Altered photic and non-photic phase shifts in 5-HT(1A) receptor knockout mice.
Smith VM; Sterniczuk R; Phillips CI; Antle MC
Neuroscience; 2008 Dec; 157(3):513-23. PubMed ID: 18930788
[TBL] [Abstract][Full Text] [Related]
20. Role of cerebellar dopamine D(3) receptors in modulating exploratory locomotion and cataleptogenicity in rats.
Shimizu S; Tatara A; Sato M; Sugiuchi T; Miyoshi S; Andatsu S; Kizu T; Ohno Y
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Apr; 50():157-62. PubMed ID: 24368396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
